"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 11 | 20 | 31 |
| 1996 | 21 | 69 | 90 |
| 1997 | 24 | 71 | 95 |
| 1998 | 21 | 79 | 100 |
| 1999 | 49 | 74 | 123 |
| 2000 | 48 | 98 | 146 |
| 2001 | 43 | 137 | 180 |
| 2002 | 70 | 176 | 246 |
| 2003 | 51 | 187 | 238 |
| 2004 | 42 | 132 | 174 |
| 2005 | 64 | 117 | 181 |
| 2006 | 76 | 102 | 178 |
| 2007 | 61 | 97 | 158 |
| 2008 | 69 | 121 | 190 |
| 2009 | 64 | 99 | 163 |
| 2010 | 52 | 85 | 137 |
| 2011 | 61 | 68 | 129 |
| 2012 | 49 | 64 | 113 |
| 2013 | 59 | 50 | 109 |
| 2014 | 55 | 52 | 107 |
| 2015 | 57 | 50 | 107 |
| 2016 | 49 | 36 | 85 |
| 2017 | 44 | 37 | 81 |
| 2018 | 40 | 32 | 72 |
| 2019 | 54 | 23 | 77 |
| 2020 | 37 | 20 | 57 |
| 2021 | 31 | 22 | 53 |
| 2022 | 4 | 22 | 26 |
| 2023 | 2 | 12 | 14 |
| 2024 | 4 | 15 | 19 |
| 2025 | 0 | 2 | 2 |
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors. Breast Cancer Res. 2025 Jan 16; 27(1):8.
-
Next generation thiazolyl ketone inhibitors of cytosolic phospholipase A2 α for targeted cancer therapy. Nat Commun. 2025 Jan 02; 16(1):164.
-
Effective drug design screening in bacterial glycolytic enzymes via targeting alternative allosteric sites. Arch Biochem Biophys. 2024 Dec; 762:110190.
-
Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators. Sci Rep. 2024 10 19; 14(1):24598.
-
Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia. Curr Treat Options Oncol. 2024 Nov; 25(11):1345-1353.
-
Synthesis, optimization and antitumor activity evaluation of sulfonyl benzoyl hydrazide derivatives as novel human LSD1 inhibitors. Bioorg Med Chem Lett. 2024 Dec 01; 114:129982.
-
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol. 2024 Oct 03; 26(10):1805-1822.
-
Direct RAS inhibitors turn 10. Nat Chem Biol. 2024 Oct; 20(10):1238-1241.
-
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533.
-
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024 Dec; 35(12):1138-1147.